|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...2728293031323334353637...4041» |
- Trial completion: Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells (clinicaltrials.gov) - Apr 1, 2013
P1, N=56, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed
- Trial termination: Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II (clinicaltrials.gov) - Mar 31, 2013
P2, N=18, Terminated, Sponsor: Louisiana State University Health Sciences Center in New Orleans
Recruiting --> Completed Recruiting --> Terminated; Unusual high frequency of elevated liver function tests.
- amiloride hydrochloride / Generic mfg.
Enrollment open: ACTION: Amiloride Clinical Trial In Optic Neuritis (clinicaltrials.gov) - Mar 25, 2013
P2, N=46, Recruiting, Sponsor: University of Oxford
Recruiting --> Terminated; Unusual high frequency of elevated liver function tests. Not yet recruiting --> Recruiting
- | dalfampridine / Generic mfg.
Enrollment closed: Dalfampridine for Imbalance in Multiple Sclerosis (clinicaltrials.gov) - Mar 24, 2013
P2, N=24, Active, not recruiting, Sponsor: Oregon Health and Science University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | ambrisentan / Generic mfg.
Trial completion: Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet (clinicaltrials.gov) - Mar 21, 2013
P=N/A, N=20, Completed, Sponsor: Soumya Chatterjee
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- glatiramer acetate / Generic mfg.
Trial completion: GASWI: A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months (clinicaltrials.gov) - Mar 20, 2013
P=N/A, N=60, Completed, Sponsor: University at Buffalo
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion: Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate (clinicaltrials.gov) - Mar 19, 2013
P4, N=40, Completed, Sponsor: Brown, Theodore R., M.D., MPH
Recruiting --> Completed Recruiting --> Completed
- mexiletine / Generic mfg.
New P4 trial: Mexiletine for the Treatment of Muscle Cramps in ALS (clinicaltrials.gov) - Mar 12, 2013
P4, N=30, Recruiting, Sponsor: Bjorn Oskarsson, MD
- ||| Enrollment closed, Patient reported outcomes: Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (clinicaltrials.gov) - Mar 12, 2013
P4, N=313, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Active, not recruiting
- tamoxifen / Generic mfg.
Trial completion: SDALS-001: Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 11, 2013
P2, N=60, Completed, Sponsor: Nazem Atassi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | vinorelbine tartrate / Generic mfg., gemcitabine / Generic mfg.
Enrollment change: Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 11, 2013
P2, N=33, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=26 --> 33
- | olesoxime (TRO19622) / Roche
New P1 trial: Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. (clinicaltrials.gov) - Mar 7, 2013
P1, N=44, Active, not recruiting, Sponsor: Trophos
- GSK2618960 / GSK
New P1 trial: A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Mar 7, 2013
P1, N=16, Terminated, Sponsor: GlaxoSmithKline
- || dalfampridine / Generic mfg.
Trial completion: Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials. (clinicaltrials.gov) - Mar 6, 2013
P3, N=38, Completed, Sponsor: Biogen Idec
N=26 --> 33 Active, not recruiting --> Completed
- Enrollment change: Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome (clinicaltrials.gov) - Mar 6, 2013
P=N/A, N=7, Completed, Sponsor: Children's Research Institute
Active, not recruiting --> Completed N=10 --> 7
- Trial completion: Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome (clinicaltrials.gov) - Mar 6, 2013
P=N/A, N=7, Completed, Sponsor: Children's Research Institute
N=10 --> 7 Recruiting --> Completed
- | dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
New P2 trial: Clinical Trial Nuedexta in Subjects With ALS (clinicaltrials.gov) - Mar 5, 2013
P2, N=60, Recruiting, Sponsor: Center for Neurologic Study, La Jolla, California,
- Enrollment open: SAMSPAP: Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial (clinicaltrials.gov) - Mar 2, 2013
P=N/A, N=65, Recruiting, Sponsor: McGill University
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial termination: Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology (clinicaltrials.gov) - Feb 28, 2013
P=N/A, N=5, Terminated, Sponsor: Drexel University College of Medicine
Recruiting --> Terminated; The study was discontinued due to low enrollment. A survey has been implemented in place of a formal study.
- Trial termination: Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient (clinicaltrials.gov) - Feb 28, 2013
P=N/A, N=1, Terminated, Sponsor: Drexel University College of Medicine
A survey has been implemented in place of a formal study. Recruiting --> Terminated; New protocol was developed based on preliminary results from this study.
- Trial termination: Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS). (clinicaltrials.gov) - Feb 28, 2013
P=N/A, N=10, Terminated, Sponsor: Drexel University College of Medicine
Recruiting --> Terminated; New protocol was developed based on preliminary results from this study. Recruiting --> Terminated; Terminated due to difficulty enrolling subjects.
- Enrollment change: BCI: EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Feb 28, 2013
P=N/A, N=150, Recruiting, Sponsor: Drexel University College of Medicine
Recruiting --> Terminated; Terminated due to difficulty enrolling subjects. N=50 --> 150
- Enrollment change: Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology (clinicaltrials.gov) - Feb 28, 2013
P=N/A, N=5, Terminated, Sponsor: Drexel University College of Medicine
N=50 --> 150 N=100 --> 5
- Enrollment change: Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient (clinicaltrials.gov) - Feb 28, 2013
P=N/A, N=1, Terminated, Sponsor: Drexel University College of Medicine
N=100 --> 5 N=25 --> 1
- Enrollment change: Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS). (clinicaltrials.gov) - Feb 28, 2013
P=N/A, N=10, Terminated, Sponsor: Drexel University College of Medicine
N=25 --> 1 N=40 --> 10
- Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed: CogMS: Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients (clinicaltrials.gov) - Feb 28, 2013
P4, N=60, Active, not recruiting, Sponsor: Clinique Neuro-Outaouais
N=40 --> 10 Recruiting --> Active, not recruiting
- Trial completion: Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population (clinicaltrials.gov) - Feb 28, 2013
P=N/A, N=25, Completed, Sponsor: Drexel University College of Medicine
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| rHIgM22 / Acorda
New P1 trial: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (clinicaltrials.gov) - Feb 28, 2013
P1, N=71, Recruiting, Sponsor: Acorda Therapeutics
- | GSK239512 / GSK
New P1 trial: GSK239512 DDI Study (clinicaltrials.gov) - Feb 28, 2013
P1, N=22, Completed, Sponsor: GlaxoSmithKline
- amiloride hydrochloride / Generic mfg.
New P2 trial: ACTION: Amiloride Clinical Trial In Optic Neuritis (clinicaltrials.gov) - Feb 27, 2013
P2, N=46, Recruiting, Sponsor: University of Oxford
- |||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment open: Dose-finding Study of MT-1303 (clinicaltrials.gov) - Feb 27, 2013
P2, N=400, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change: Teleconference Fatigue Management for People With Multiple Sclerosis (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=190, Completed, Sponsor: University of Illinois at Chicago
Not yet recruiting --> Recruiting N=140 --> 190
- ||||| Radicava (edaravone) / Mitsubishi Tanabe
Enrollment change: Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Feb 26, 2013
P3, N=181, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
N=140 --> 190 N=140 --> 181
- Trial completion: Teleconference Fatigue Management for People With Multiple Sclerosis (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=190, Completed, Sponsor: University of Illinois at Chicago
N=140 --> 181 Recruiting --> Completed
- Enrollment change: Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=60, Completed, Sponsor: Meir Medical Center
Recruiting --> Completed N=50 --> 60
- Trial completion: Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=60, Completed, Sponsor: Meir Medical Center
N=50 --> 60 Recruiting --> Completed
- Clinical: Power Over Pain (POP) Study (clinicaltrials.gov) - Feb 25, 2013
P=N/A, N=144, Recruiting, Sponsor: University of Washington
- l-methylfolate / Generic mfg.
Enrollment closed: Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) (clinicaltrials.gov) - Feb 25, 2013
P1, N=40, Active, not recruiting, Sponsor: University of Iowa
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion, Compliance: An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters (clinicaltrials.gov) - Feb 21, 2013
P=N/A, N=133, Completed, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Rebif (human IFN-?-1a) / EMD Serono
Trial completion, Adherence: An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif (clinicaltrials.gov) - Feb 21, 2013
P=N/A, N=912, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Betaseron (IFN-β-1b) / Bayer
New P4 trial: BENEFIT 11: Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis (clinicaltrials.gov) - Feb 19, 2013
P4, N=400, Recruiting, Sponsor: Bayer
- |||||| Enrollment open: OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Feb 18, 2013
P3, N=700, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Rebif (human IFN-β-1a) / EMD Serono
Enrollment closed, Adherence: MEASURE: Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects (clinicaltrials.gov) - Feb 18, 2013
P=N/A, N=188, Active, not recruiting, Sponsor: Merck KGaA
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche
Trial withdrawal: Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment (clinicaltrials.gov) - Feb 17, 2013
P2, N=0, Withdrawn, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- Rituxan (rituximab) / Roche
Enrollment change: Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment (clinicaltrials.gov) - Feb 17, 2013
P2, N=0, Withdrawn, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Recruiting --> Withdrawn N=30 --> 0
- | Enrollment open, HEOR: A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 (clinicaltrials.gov) - Feb 17, 2013
P4, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
N=30 --> 0 Not yet recruiting --> Recruiting
- ||||| Rebif (human IFN-β-1a) / EMD Serono
New P4 trial, HEOR, Adherence: RebiQoL: A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device (clinicaltrials.gov) - Feb 11, 2013
P4, N=130, Recruiting, Sponsor: Merck KGaA
- Biomarker, Trial termination: BioCogS: A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein). (clinicaltrials.gov) - Feb 10, 2013
P=N/A, N=29, Terminated, Sponsor: Nantes University Hospital
Not yet recruiting --> Recruiting Recruiting --> Terminated; Difficulties of recruitment in a randomization arm
- Biomarker, Enrollment change: BioCogS: A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein). (clinicaltrials.gov) - Feb 10, 2013
P=N/A, N=29, Terminated, Sponsor: Nantes University Hospital
Recruiting --> Terminated; Difficulties of recruitment in a randomization arm N=39 --> 29
- | disitertide (P144) / Avadel, Digna Biotech
Enrollment change: Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study (clinicaltrials.gov) - Feb 7, 2013
P2, N=38, Completed, Sponsor: ISDIN
N=39 --> 29 N=98 --> 38